Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Dec 2024 | FROM AKERO THERAPEUTICS

Improvement of liver fibrosis in efruxifermin-treated patients with MASH:correlation between conventional histopathology, AI-based digital histopathology, and non-invasive biomarkers of fibrosis

Erik J Tillman, Doreen Chan, Reshma Shringarpure, Yukti Choudhury, Elaine Chng, Dean Tai, Kitty Yale, Tim Rolph Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution

Nov 2024 | From Akero Therapeutics

Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups, and Improvements Were Associated With Changes in Biomarkers

Mazen Noureddin, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Matt Minerva, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A. Harrison The Liver Meeting 2024 (AASLD)

Nov 2024 | From Akero Therapeutics

Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study

Mazen Noureddin, Cynthia Behling, Pierre Bedossa, Lan Shao, Elaine Chng, Yukti Choudhury, Dean Tai, Doreen Chan, Erica Fong, Brittany De Temple, Matt Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A Harrison The Liver Meeting 2024 (AASLD)

Nov 2024 | From Akero Therapeutics

AI and Digital-Based Pathology Corroborate Reduction in Fibrosis Observed by Conventional Pathology with Efruxifermin Treatment of Patients with F2-F3 MASH in the HARMONY Study

Mazen Noureddin, Dean Tai, Elaine Chng, Yukti Choudhury, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matt Minerva, Mark Burch, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A Harrison The Liver Meeting 2024 (AASLD)

Jun 2024 | From Akero Therapeutics

Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH

Erik J Tillman, Doreen C Chan, Reshma Shringarpure, Diana J Leeming, Morten A Karsdal, Stephen A Harrison, Andrew Cheng, Kitty Yale, Tim Rolph 2024 International Liver Congress (EASL)

Jun 2024 | From Akero Therapeutics

LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

Vlad Ratziu 2024 International Liver Congress (EASL)

May 2024 | From Akero Therapeutics

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Stephen A. Harrison, Tim Rolph, Maddie Knot, Julie Dubourg Journal of Hepatology

Mar 2024 | From Akero Therapeutics

Efruxifermin significantly improved collagen biomarkers, consistent with beneficial ECM remodeling in patients with F2-F3 fibrosis due to MASH

Erik J Tillman, Doreen C Chan, Reshma Shringarpure, Diana J Leeming, Morten A Karsdal, Andrew Cheng, Kitty Yale, Tim Rolph Keystone Symposium MASH AND FIBROSIS: From Molecular Phenotypes to Precision Therapeutics

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline